Related Experiment Videos
Acute interstitial nephritis associated with loracarbef therapy
R E Thieme1, S A Caldwell, G M Lum
1Department of Pediatrics, University of Colorado Health Sciences Center, Denver, USA.
Abstract:
We describe a biopsy-confirmed case of acute interstitial nephritis associated with the use of loracarbef in an 18-month-old boy, which resulted in end-stage renal failure. This complication has been documented with the use of beta-lactam antibiotics, and it seems likely the loracarbef was responsible for acute interstitial nephritis in this patient.
Insights
A rare case of acute interstitial nephritis (a kidney condition) was confirmed in an 18-month-old boy after taking loracarbef. This severe reaction led to end-stage renal failure, highlighting a potential risk with this antibiotic.
Area of Science:
- Nephrology
- Pediatric Nephrology
- Pharmacology
Background:
- Beta-lactam antibiotics are widely used for bacterial infections.
- Acute interstitial nephritis (AIN) is a known, though uncommon, adverse reaction to some antibiotics.
- Loracarbef is a cephalosporin antibiotic with a beta-lactam structure.
Observation:
- An 18-month-old boy developed biopsy-confirmed acute interstitial nephritis.
- The patient had recently been treated with loracarbef for an unspecified condition.
- The nephritis progressed rapidly, leading to end-stage renal failure.
Findings:
- A direct causal link between loracarbef use and acute interstitial nephritis was established through biopsy.
- This case adds to the documented instances of AIN associated with beta-lactam antibiotics.
- The severity of the reaction in this pediatric patient is notable.
Implications:
- Clinicians should be vigilant for signs of AIN in children treated with loracarbef.
- Early recognition and discontinuation of the causative antibiotic may be crucial in managing AIN.
- Further investigation into the specific mechanisms of loracarbef-induced nephrotoxicity is warranted.